<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886389</url>
  </required_header>
  <id_info>
    <org_study_id>59</org_study_id>
    <nct_id>NCT03886389</nct_id>
  </id_info>
  <brief_title>Breast Cancer Diet Intervention Study</brief_title>
  <acronym>BCDIS</acronym>
  <official_title>The Effects of Insulin and Insulin-related Characteristics, and Short-Term Low-glycemic and High-glycemic Carbohydrate Intervention on Breast Cancer Biomarkers and Survival</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have already proven that Mitotic Activity Index (MAI)is the most robust
      measure of proliferation in breast cancer tissue.

      The purpose was to study whether 18 and 2-4 hours pre-operative per-oral carbohydrate loading
      (often given in gastrointestinal surgery i.e. enhanced recovery after surgery=ERAS)
      influences proliferation in the tumor, serum insulin characteristics, metabolic profile and
      survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been postulated that a &quot;Western-style&quot; diet, rich in carbohydrates (especially high
      glycemic carbohydrates) may have an effect on the incidence of breast cancer, and perhaps
      also prognosis. This may be mediated through the insulin-related pathways in breast cells
      which may show insulin-dependent proliferation, which may alter outcome.

      Aims:

      To study:

        1. The inter-patient variation in insulin and insulin-related characteristics in the blood
           taken just before the operation from breast cancer patients, on a usual pre-operative
           fasting schedule;

        2. The influence of the variation in insulin and insulin-related characteristics on
           proliferation and other cell biological features in the breast cancers of these
           patients;

        3. Whether 4 and 18-hours pre-operative hyperglycaemic glucose loading (to reduce
           postoperative insulin resistance) influences proliferation (Mitotic Activity Index (MAI)
           and other cell biological features in breast cancer*

        4. The influence of the short-term effect of a pre-operative low-glycaemic carbohydrate
           isocaloric diet on proliferation and other cell biological features of the primary
           breast cancer cells (Low-glycemic isocaloric diet intervention study);

        5. Epidemiological risk factors: The correlation between epidemiological risk factors,
           insulin and insulin-related characteristics, proliferation, cell biological features and
           other biomarkers in breast cancer patients.

        6. Estrogen Receptor positive tumors will be analyses separately.

        7. Relapse free survival

        8. Breast Cancer Specific Survival.

      The Short-term effect of carbohydrates will be assessed in a randomized intervention study,
      where 30 patients receive oral carbohydrates 18 and 4 hours before surgery and 30 patients
      receive fasting procedure/water.

      Primary Outcome

      1. Proliferation in the tumor as measured by MAI.

      Secondary Outcomes:

        1. Serum insulin characteristics (S-insulin, S- insulin c-peptide, S-IGF and S-IGFBP3) will
           be measured at various peri-surgical timepoints

        2. Changes in metabolic profile* in the tumor and in serum samples

        3. Patient Reported Outcome Measures (PROM) on well being

        4. Relapse free survival

        5. Breast Cancer Specific Survival

             -  Metabolic profile assessed by High Resolution Magnetic Resonance Spectroscopy
                (HR-MRS) in the tumor and in serum samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2009</start_date>
  <completion_date type="Actual">July 7, 2017</completion_date>
  <primary_completion_date type="Actual">July 7, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitotic Activity Index (MAI)</measure>
    <time_frame>Trough completion of surgery of all included patients, an average of 1,5 years</time_frame>
    <description>Proliferation in invasive front in tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>S-Insulin</measure>
    <time_frame>Analysed in serum samples at 5 time points; At inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30)</time_frame>
    <description>Secretion of insulin into serum; unit, mIE/L (milli international units pr liter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Well being after surgery</measure>
    <time_frame>Day 1,2,3,4,5,6 and 7 after surgery</time_frame>
    <description>Patient Reported Outcome Measures (Questionaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Resolution Magnetic Resonance Spectroscopy (HR-MRS) profiling of specific metabolites</measure>
    <time_frame>Immediately after surgery: tumor is fresh frozen. High Resolution Magnetic Resonance Spectroscopy (HR-MRS) will be done in the fresh frozen tumor and deep frozen serum samples (=as for insulin characteristics)</time_frame>
    <description>Metabolic profiling in the primary tumor and in the serum samples; measure content of lactate, glycine, choline, fatty acids and lipoproteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>Until 8 years (97 months of follow up)</time_frame>
    <description>Time from surgery to a relapse (Loco-regional, contralateral and systemic) is experienced</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer Specific Survival</measure>
    <time_frame>8 years follow-up (97 months of follow up)</time_frame>
    <description>Time from surgery to dead of disease or all other causes of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-insulin c-peptide,</measure>
    <time_frame>Analysed in serum samples at 5 time points; At inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30)</time_frame>
    <description>Measure of total insulin secreted; unit, nM (nano molar)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-IGF1</measure>
    <time_frame>Analysed in serum samples at 5 time points; At inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30)</time_frame>
    <description>Measure of Insulin growth factor type 1; unit, nM (nano molar)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-IGFBP3</measure>
    <time_frame>Analysed in serum samples at 5 time points; At inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30)</time_frame>
    <description>Measure of Insulin growth factor binding protein 3; unit mg/L (milligram per liter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR</measure>
    <time_frame>Trough completion of surgery of all included patients, an average of 1,5 years</time_frame>
    <description>Expression of Progesteron Receptor in the primary tumor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Early-stage Breast Cancer</condition>
  <condition>Carbohydrate Engorgement</condition>
  <condition>Proliferation</condition>
  <condition>Insulin Resistance</condition>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Carbohydrate/intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breast cancer patients receive 2 x preoperative carbohydrate loading [PreOP(TM)] before surgery; the 1st dose 18 hours before and 2nd dose 2-4 hours before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Breast cancer patients receive standard prep fasting procedure with nil food per os 8-10 hours before surgery, drinking tap water until 2 hours before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PreOP</intervention_name>
    <description>Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.</description>
    <arm_group_label>Carbohydrate/intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All consecutive operable patients in 2009-2010, with a clinical and/or radiologic
             and/or cytologic diagnosis of primary breast cancer, unless the exclusion criteria
             apply.

        Exclusion Criteria:

          1. Non-operable patients (i.e&quot; patients with T3-4 (&gt;5 cm) disease or distant metastases
             at the time of operation).

          2. All patients who refuse to participate.

          3. All patients with DCIS, micro-invasive cancer &lt; 2mm diameter or tumors with histologic
             poor-quality material.

          4. Co-morbidity (Insulin dependent Diabetes Mellitus, Cushing syndrome, previous or
             concurrent cancers except CIN and non-melanomatous skin cancer.

          5. Mental inability to participate.

          6. Persons allergic to one of the compounds in any of the two diets.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer is 100 x more frequent in women than in men.</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svein Skeie, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helse Stavanger HF; Stavanger University Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, Janssen EA. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol. 2005 Sep 1;23(25):5993-6001.</citation>
    <PMID>16135467</PMID>
  </reference>
  <reference>
    <citation>Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, SÃ¸iland H, Janssen EA, Zur Hausen A. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat. 2009 May;115(2):241-54. doi: 10.1007/s10549-008-0126-y. Epub 2008 Jul 30. Review.</citation>
    <PMID>18665447</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helse Stavanger HF</investigator_affiliation>
    <investigator_full_name>Haavard Soiland</investigator_full_name>
    <investigator_title>Professor PhD</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Estrogen receptor positive</keyword>
  <keyword>Proliferation</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>PROMs</keyword>
  <keyword>NMRI</keyword>
  <keyword>RFS</keyword>
  <keyword>BCSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All data will be available to all researches involved in the study included the statistician allocated to the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

